Dacogen

(Decitabine)

ApprovedSmall molecule

Decitabine is used to treat certain blood cancers, particularly myelodysplastic syndromes (abnormal blood cell development). It works by helping to restore normal function to blood-forming cells that have become abnormal.[2] Dacogen is currently approved and in use across 59 indications[4].[1]

Dacogen is one of 871 small molecule programs targeting Leukemia. It is currently in Approved.

Indications

319

Total Trials

Active Trials

870

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

LeukemiaCompleted

Colorectal CancerNot yet recruiting

Ovarian CancerUnknown status

Chronic Myelomonocytic LeukemiaTerminated

Myeloid LeukemiaActive, not recruiting

AnemiaActive, not recruiting

MedulloblastomaApproved

T Lymphoblastic Leukemia/lymphomaApproved

Breast CancerApproved

Lymphoid NeoplasmApproved

LeukemiaPhase 2

Completed

Colorectal CancerPhase 2

Not yet recruiting

Ovarian CancerPhase 2

Unknown status

Chronic Myelomonocytic LeukemiaPhase 2

Terminated

Myeloid LeukemiaApproved

Active, not recruiting

AnemiaApproved

Active, not recruiting

MedulloblastomaApproved

Approved

T Lymphoblastic Leukemia/lymphomaApproved

Approved

Breast CancerApproved

Approved

Lymphoid NeoplasmApproved

Approved

Showing 10 of 59 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Lexiscan

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Poor Graft Function

NCT05907499

Phase 3Active, not recruiting

AIN

NCT04229979

Phase 1Recruiting

Myeloid Malignancies

NCT04187703

Phase 1Active, not recruiting

Myeloid Neoplasm

NCT05455294

Q1 2027

Phase 1Active, not recruiting

MDS

NCT03974217

Phase 1Recruiting

Leukemia

NCT07044544

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia44 trials

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Completed·UUniversity of Nebraska·Phase 2·NCT03226418·75 enrolled

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00416598·546 enrolled

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT02029417·2 enrolled

Show 41 more trials

Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00703300·19 enrolled

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·SSumithira Vasu·Phase 1·NCT02316964·8 enrolled

GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia

Terminated·YYale University·Phase 2·NCT04051996·1 enrolled

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

Completed·CCardiff Oncology·Phase 1/2·NCT03303339·72 enrolled

Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Suspended· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT04485052·222 enrolled

Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2/3·NCT00398983·50 enrolled

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Terminated·KKartos Therapeutics, Inc.·Phase 1/2·NCT04113616·70 enrolled

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01627041·178 enrolled

A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·UUniversity of Rochester·Phase 1·NCT00861874·13 enrolled

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

Completed·WWeill Medical College of Cornell University·Phase 1·NCT01352650·71 enrolled

Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia

Completed·UUniversity Hospital Freiburg·Phase 2·NCT00867672·204 enrolled

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Terminated·DDavid Iberri·Phase 2·NCT01846624·13 enrolled

Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia

Unknown status·CChunyan Ji·Phase 3·NCT02985372·30 enrolled

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·BBhavana Bhatnagar·Phase 1·NCT02093403·25 enrolled

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Recruiting·BBio-Path Holdings, Inc.·Phase 1·NCT05190471·48 enrolled

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06401603·30 enrolled

Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients

Unknown status·JJianxiang Wang·Phase 3·NCT01633099·46 enrolled

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1/2·NCT02632721·49 enrolled

Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）

Completed·—·Phase 1/2·NCT01690507·29 enrolled

Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01420926·165 enrolled

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial

Unknown status·HHuihan Wang·Phase 3·NCT05382390·130 enrolled

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03164057·206 enrolled

Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00492401·55 enrolled

Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)

Completed· Eisai logo

Eisai·Phase 2·NCT00358644·55 enrolled

Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01786343·74 enrolled

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Terminated·WWashington University School of Medicine·Phase 2·NCT03063203·17 enrolled

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·EECOG-ACRIN Cancer Research Group·Phase 3·NCT02085408·727 enrolled

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

Terminated·MMayo Clinic·Phase 2·NCT02634827·1 enrolled

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT02257138·30 enrolled

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03041688·58 enrolled

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT03063944·37 enrolled

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Terminated·SSanjay Mohan·Phase 2·NCT05799079·1 enrolled

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01707004·20 enrolled

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT04353479·29 enrolled

The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype

Unknown status·TThe University of Hong Kong·Phase 2·NCT03080766·20 enrolled

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Active, not recruiting·—·Phase 1·NCT05222984·17 enrolled

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT04277442·1 enrolled

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

Active, not recruiting·UUniversity of Chicago·Phase 1·NCT03844815·26 enrolled

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Completed· AbbVie logo

AbbVie·Phase 3·NCT03941964·60 enrolled

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Terminated· Gilead logo

Gilead·Phase 1/2·NCT02343939·148 enrolled

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia

Completed·AAlison Walker·Phase 1·NCT01798901·13 enrolled

Myelodysplastic Syndrome27 trials

Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

Withdrawn·LLi Junmin·Phase 3·NCT03377725

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01812252·50 enrolled

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01130506·17 enrolled

Show 24 more trials

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

Withdrawn·WWashington University School of Medicine·Phase 1·NCT02564536

Decitabine in Treating Patients With Myelodysplastic Syndrome

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003361·75 enrolled

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Recruiting·PPureTech·Phase 1·NCT05829226·90 enrolled

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01567059·34 enrolled

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00778375·122 enrolled

Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure

Unknown status·KKing's College London·Phase 2·NCT01133886·50 enrolled

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT03092674·76 enrolled

Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant

Completed·WWashington University School of Medicine·Phase 1·NCT00986804·24 enrolled

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Recruiting·SSyntrix Biosystems, Inc.·Phase 1·NCT04245397·151 enrolled

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed· Pfizer logo

Pfizer·Phase 2·NCT01546038·255 enrolled

Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT01809392·15 enrolled

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00882102·43 enrolled

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Completed·—·Phase 1/2·NCT01165996·25 enrolled

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

Completed· Amgen logo

Amgen·Phase 2·NCT00321711·69 enrolled

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00067808·128 enrolled

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Active, not recruiting·TThomas Jefferson University·Phase 1·NCT05564650·6 enrolled

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00043134·220 enrolled

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1·NCT03358719·8 enrolled

An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)

Completed·JJohnson & Johnson Taiwan Ltd·Phase 2·NCT00744757·37 enrolled

Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01720225·113 enrolled

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03404193·235 enrolled

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00414310·153 enrolled

Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)

Suspended·SSclnow Biotechnology Co., Ltd.·Phase 1/2·NCT03184935·40 enrolled

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01834248·9 enrolled

Myelodysplastic Syndromes15 trials

LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Completed·WWashington University School of Medicine·Phase 1/2·NCT00691938·52 enrolled

Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 4·NCT01806116·30 enrolled

Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes

Recruiting·WWest Virginia University·Phase 1/2·NCT06923488·26 enrolled

Show 12 more trials

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Completed·WWashington University School of Medicine·Phase 2·NCT01687400·114 enrolled

Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01593670·9 enrolled

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00075010·54 enrolled

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00382200·54 enrolled

Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Completed·WWashington University School of Medicine·Phase 1·NCT00671697·13 enrolled

A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)

Recruiting·TTreebough Therapies·Phase 1·NCT07006025·20 enrolled

A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes

Completed· Eisai logo

Eisai·Phase 2·NCT00260065·99 enrolled

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00903760·42 enrolled

Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00049582·36 enrolled

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

Withdrawn· Takeda logo

Takeda·Phase 2·NCT04985656

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT01729845·52 enrolled

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02469415·3 enrolled

Lymphoma9 trials

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Unknown status·—·Phase 2·NCT04279379·20 enrolled

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Unknown status·SSouthwest Hospital, China·Phase 3·NCT03553537·100 enrolled

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Unknown status·—·Phase 2·NCT03250962·280 enrolled

Show 6 more trials

A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

Unknown status·MMingzhi Zhang·Phase 4·NCT03579082·60 enrolled

Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00109824·42 enrolled

Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas

Unknown status·HHan weidong·Phase 1/2·NCT01799083·100 enrolled

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00089089·42 enrolled

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Recruiting·—·Phase 1/2·NCT04337606·100 enrolled

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Unknown status·—·Phase 2·NCT04233294·100 enrolled

Leukemia6 trials

A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00349596·40 enrolled

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

Completed·FFox Chase Cancer Center·Phase 2·NCT02190695·92 enrolled

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03132454·32 enrolled

Show 3 more trials

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Terminated· Eisai logo

Eisai·Phase 2·NCT01177540·25 enrolled

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Terminated· AbbVie logo

AbbVie·Phase 1·NCT02203773·212 enrolled

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT07044544·20 enrolled

69 more indications

Conditioning5 trials

Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT04098653·196 enrolled

10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

Completed·RRadboud University Medical Center·Phase 2·NCT02252107·46 enrolled

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT04123392·196 enrolled

Show 2 more trials

Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03530085·60 enrolled

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Completed·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT02744742·202 enrolled

Chemotherapy3 trials

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT01483690·23 enrolled

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Recruiting· Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.·Phase 3·NCT05586074·324 enrolled

Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice

Unknown status·UUlsan University Hospital··NCT02698124·136 enrolled

Stem Cell Transplant3 trials

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Recruiting·BBenjamin Tomlinson·Phase 1/2·NCT06129734·20 enrolled

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Withdrawn·NNorthside Hospital, Inc.·Phase 2·NCT06337331

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Recruiting·FFred Hutchinson Cancer Center·Phase 1/2·NCT06928662·36 enrolled

Chronic Myelomonocytic Leukemia3 trials

Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)

Completed·GGroupe Francophone des Myelodysplasies·Phase 2·NCT01098084·41 enrolled

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recruiting·MMayo Clinic·Phase 2·NCT03418038·80 enrolled

Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia

Completed·FFondazione Italiana Sindromi Mielodisplastiche-ETS·Phase 2·NCT01251627·43 enrolled

Relapsed or Refractory3 trials

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT04493099

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT01607645·7 enrolled

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Recruiting·HHan weidong·Phase 1/2·NCT02961101·250 enrolled

Fallopian Tube Cancer3 trials

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01673217·18 enrolled

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1·NCT03017131·9 enrolled

Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Terminated·CCancer Research UK·Phase 2·NCT00748527·134 enrolled

Ovarian Cancer3 trials

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Recruiting·LLoyola University·Phase 2·NCT05983276·40 enrolled

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03467178·119 enrolled

Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer

Completed·IIndiana University·Phase 1/2·NCT00477386·28 enrolled

MDS3 trials

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Terminated· Novartis logo

Novartis·Phase 2·NCT04878432·39 enrolled

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Active, not recruiting·—·Phase 1·NCT03974217·13 enrolled

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Terminated· Eisai logo

Eisai·Phase 4·NCT01011283·26 enrolled

Efficacy2 trials

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06441097·152 enrolled

Efficacy of Decitabine in Clearance of MRD

Withdrawn·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT03021395

Myeloid Malignancies2 trials

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Completed·MMayo Clinic·Phase 1·NCT02129101·63 enrolled

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Recruiting·BBenjamin Tomlinson·Phase 1·NCT04187703·20 enrolled

High Risk2 trials

Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients

Completed·UUniversity of Rochester·Phase 1/2·NCT02109744·27 enrolled

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Completed· Novartis logo

Novartis·Phase 1·NCT03066648·241 enrolled

Chronic Myelogenous Leukemia2 trials

Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00275080·80 enrolled

Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00002832·14 enrolled

AML2 trials

Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML

Completed·SSarit Assouline·Phase 2·NCT02073838·23 enrolled

"InDACtion" vs "3+7" Induction in AML

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT02172872·606 enrolled

Treatment2 trials

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

Completed·JJohn Mascarenhas·Phase 1/2·NCT02076191·49 enrolled

Biomarker Guided Treatment in DLBCL

Unknown status·RRuijin Hospital·Phase 2·NCT04025593·128 enrolled

Acute Leukemia2 trials

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Unknown status·TThe First Affiliated Hospital of Soochow University·N/A·NCT05805072·20 enrolled

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01794702·65 enrolled

Trial2 trials

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Terminated·DDelta-Fly Pharma, Inc.·Phase 3·NCT03926624·167 enrolled

Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00479232·71 enrolled

Efficacy and Safety2 trials

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

Not yet recruiting·RRuijin Hospital·Phase 3·NCT06297772·220 enrolled

Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent

Unknown status·SShandong University·Phase 2·NCT03045510·50 enrolled

Melanoma2 trials

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

Completed·CCalifornia Cancer Consortium·Phase 1·NCT00002980

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00791271·17 enrolled

Acute Lymphoblastic Leukemia2 trials

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00882206·15 enrolled

Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00042796·21 enrolled

Randomized2 trials

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

Completed·GGroupe Francophone des Myelodysplasies·Phase 3·NCT02214407·170 enrolled

Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects

Completed·EEpiDestiny, Inc.·Phase 1·NCT03828084·16 enrolled

Relapsed/Refractory1 trial

Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

Unknown status·—·Phase 1/2·NCT03346642·30 enrolled

Malignancies1 trial

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00037817·34 enrolled

Arsenic Trioxide1 trial

Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS

Unknown status·RRuijin Hospital·Phase 1·NCT03855371·5 enrolled

Newly Diagnosed1 trial

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT02921061·28 enrolled

AIN1 trial

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active, not recruiting·SSellas Life Sciences Group·Phase 3·NCT04229979·127 enrolled

Metastatic Melanoma1 trial

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

Completed·HHussein Tawbi·Phase 1/2·NCT00715793·39 enrolled

Hematologic Cancer1 trial

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00357708·50 enrolled

Colorectal Cancer1 trial

Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)

Completed·UUniversitair Ziekenhuis Brussel·Phase 1/2·NCT02316028·11 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 1/2·NCT02951728·58 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Withdrawn·—·Phase 1·NCT06572631

Metastatic Solid Tumors1 trial

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00701298·30 enrolled

Patients With Advanced Solid Tumors1 trial

Decitabine in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00030615·24 enrolled

Refractory AML1 trial

Epigenetic Reprogramming in Relapse/Refractory AML

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT03263936·37 enrolled

Thalassemia1 trial

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Completed·CCarelon Research··NCT00000623·1,000 enrolled

Phase 21 trial

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

Completed·HHelsinn Healthcare SA·Phase 2·NCT01993641·45 enrolled

Induction Chemotherapy1 trial

Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML

Completed·WWeill Medical College of Cornell University·Phase 1·NCT00538876·30 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·RRuijin Hospital·Phase 2/3·NCT06972641·126 enrolled

Relapsed/Refractory AML1 trial

Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML

Recruiting·UUniversity Hospital Tuebingen·Phase 2·NCT06156579·27 enrolled

Lymphoid Malignancies1 trial

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Completed·YYogen Saunthararajah·Phase 1·NCT02846935·7 enrolled

Juvenile Myelomonocytic Leukemia1 trial

Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia

Unknown status·—··NCT03687463·6 enrolled

Immune Thrombocytopenia1 trial

A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia

Completed·SShandong University·Phase 2·NCT01568333·45 enrolled

Relapse1 trial

Epigenetic Reprogramming in Relapse AML

Terminated·MMichael Burke·Phase 1·NCT02412475·3 enrolled

Allogeneic Stem Cell Transplantation1 trial

Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation

Completed·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT03663751·14 enrolled

Oral1 trial

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

Completed·EEpiDestiny, Inc.·Phase 1·NCT05816356·10 enrolled

Non-Small Cell Lung Cancer1 trial

Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00084981·25 enrolled

AML/MDS1 trial

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT04055844·14 enrolled

Pancreatic Cancer1 trial

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Completed·MMohammed Milhem·Phase 1·NCT02959164·36 enrolled

Age1 trial

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06511882·37 enrolled

Chronic Lymphocytic Leukemia1 trial

Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00079378·84 enrolled

Advanced Malignancies1 trial

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Terminated· Novartis logo

Novartis·Phase 1/2·NCT02608268·252 enrolled

Adult AML1 trial

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

Terminated·FFox Chase Cancer Center·Phase 1/2·NCT03113071·1 enrolled

Decitabine-primed Tandem CD19/CD20 CAR T Cells1 trial

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Unknown status·—·Phase 1/2·NCT04553393·80 enrolled

Untreated AML1 trial

Decitabine and Talazoparib in Untreated AML and R/R AML

Completed·UUniversity of Maryland, Baltimore·Phase 1/2·NCT02878785·25 enrolled

Acute Respiratory Distress Syndrome1 trial

Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial

Suspended·JJohns Hopkins University·Phase 2·NCT04482621·33 enrolled

Phase IB1 trial

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Completed·BBerGenBio ASA·Phase 1/2·NCT02488408·122 enrolled

Poor Graft Function1 trial

Decitabine for Poor Graft Function Post Allo-HSCT

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT05907499·76 enrolled

Older Patients1 trial

Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT02532010·13 enrolled

Frontline1 trial

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Withdrawn·UUniversity of Florida·Phase 2·NCT05766514

Colon Cancer1 trial

Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study

Terminated·—·N/A·NCT01882660·10 enrolled

Malignant Mesothelioma1 trial

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00019825

Thrombocytopenia1 trial

Prospective Study of Patients With Thrombocytopenia Following HSCT

Completed·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT02487563·97 enrolled

Maintenance Treatment1 trial

Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML

Unknown status·SSeoul St. Mary's Hospital·Phase 1·NCT01277484·19 enrolled

Lymphoblastic Lymphoma1 trial

A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma

Unknown status·MMingzhi Zhang·Phase 4·NCT03558412·40 enrolled

Myeloid Neoplasm1 trial

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Active, not recruiting·JJacqueline Garcia, MD·Phase 1·NCT05455294·16 enrolled

Neuroblastoma1 trial

Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00075634·21 enrolled

Immune Checkpoint Inhibitors1 trial

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Unknown status·—·Phase 1/2·NCT05320640·100 enrolled

Advanced Hematologic Malignancies1 trial

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Active, not recruiting·FFoghorn Therapeutics Inc.·Phase 1·NCT04891757·144 enrolled

Prostate Cancer1 trial

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Withdrawn·RRoswell Park Cancer Institute·Phase 1/2·NCT03709550

Unspecified1 trial

Avapritinib With Decitabine in Patients With SM-AHN

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06327685·34 enrolled

Regulatory

FDA Approval Timeline[5]

May 2, 2006

DACOGEN

NDA NDA021790

Jan 28, 2014

DECITABINE

NDA NDA205582

Sources

References

[1]
ClinicalTrials.gov — 319 trial records for Decitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Dacogen drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Decitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Decitabine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA205582). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Sun Pharmaceutical Industries, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA (cytosine-5)-Methyltransferase 1 Inhibitor; DNA (cytosine-5)-Methyltransferase 3a Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Sun Pharmaceutical Industries, Inc.